Ranibizumab w leczeniu wysiękowego AMD – kilkuletnie obserwacje własne pacjentów z zachowaną dobrą ostrością wzroku mimo obecności rozległej błony neowaskularyzacji podsiatkówkowej

• Authors: Marcin Śwituła

Title variants

EN

Ranibizumab for wet AMD – several years own observations of patients with preserved good visual acuity despite of extensive subretinal neovascularization

• Languages of publication: PL

Abstracts

PL

W codziennej praktyce klinicznej wyniki leczenia zwyrodnienia plamki związanego z wiekiem w wieloletniej obserwacji – szczególnie u pacjentów z czynnikami ryzyka utraty widzenia, takimi jak duża powierzchnia błony neowaskularyzacji podsiatkówkowej – mogą się różnić od wyników uzyskanych w badaniach klinicznych. W artykule przedstawiono 3 przypadki pacjentów, u których wieloletnia terapia ranibizumabem mimo obecności dużej błony neowaskularyzacji pozwoliła zachować dobrą ostrość wzroku. Omówiono przyczyny mogące wpływać na rokowanie u pacjentów z wysiękową postacią zwyrodnienia plamki związanego z wiekiem leczonych ranibizumabem przez wiele lat.

EN

In everyday clinical practice, results of therapy for age-related macular degeneration in long-term observation, especially in patients with risk factors of visual loss like large area of subretinal neovascularization, may be different from results obtained in clinical studies. In this paper clinical cases of three patients were presented, in whom despite of large subretinal neovascularization, long- term ranibizumab therapy preserved good visual acuity. Factors influencing prognosis in patients with wet age-related macular degeneration treated with ranibizumab were analyzed.

Keywords

EN

ranibizumab; rokowanie; zwyrodnienie plamki związane z wiekiem

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2015
• Volume: 2
• Issue: 1
• Pages: 48-55

Contributors

author

Marcin Śwituła

• Centrum Medyczne MAVIT w Warszawie

References

• 1. Bressler N. Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291(15): 1900-1901.
• 2. Kaiser P, Blodi B, Shapiro H, et al; MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114(10): 1868-1875.
• 3. Brown D, Kaiser P, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432-1444.
• 4. Fung A, Lalwani G, Rosenfeld P, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143(4): 566-583.
• 5. Lalwani G, Rosenfeld P, Fung A, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group 2009; 148(1): 43-58.
• 6. Martin D, Maguire M, Fine S, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119(7): 1388-1398.
• 7. Singer M, Awh C, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012; 119(6): 1175-1183.
• 8. Rofagha S, Bhisitkul R, Boyer D, et al. SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013; 120(11): 2292-2299.
• 9. Rasmussen A, Bloch S, Fuchs J, et al. A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2013; 120(12): 2630-2636.
• 10. Coco R, Sanabria M, Castrejon M, et al. Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain. BMC Ophthalmol 2014; 14: 138.
• 11. Ying G, Huang J, Maguire M, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology 2013; 120(1): 122-129.
• 12. Korb C, Zwiener I, Lorenz K, et al. Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration – evaluation in a clinical setting. BMC Ophthalmol 2013; 13: 84.
• 13. Holz F, Bandello F, Gillies M, et al. LUMINOUS Steering Committee. Safety of ranibizumab in routine clinical practice: 1-year retrospective pooled analysis of four European neovascular AMD registries within the LUMINOUS programme. Br J Ophthalmol 2013; 97(9): 1161-1167.
• 14. Wolf A, Kampik A. Efficacy of treatment with ranibizumab in patients with wet age-related macular degeneration in routine clinical care: data from the COMPASS health services research. Graefes Arch Clin Exp Ophthalmol 2014; 252(4): 647-655.
• 15. Krüger Falk M, Kemp H, Sørensen T. Four-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatment. Am J Ophthalmol 2013; 155(1): 89-95.
• 16. Barthelmes D, Walton R, Campain A, et al; for the Fight Retinal Blindness! Project Investigators. Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data. Br J Ophthalmol 2014 Sep 23. pii: bjophthalmol-2014-305514.
• 17. Ying G, Kim B, Maguire M, et al. CATT Research Group. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials. JAMA Ophthalmol 2014; 132(8): 915-921.
• 18. Daniel E, Toth C, Grunwald J, et al; Comparison of Age-related Macular Degeneration Treatments Trials Research Group. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014; 121(3): 656-666.
• 19. Grunwald J, Daniel E, Huang J, et al; CATT Research Group. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology 2014; 121(1): 150-161.
• 20. Bhisitkul R, Mendes T, Rofagha S, et al. Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA and HORIZON studies (SEVEN-UP Study). Am J Ophthalmol 2015 Jan 29. pii: S0002-9394(15)00061-6.

• Document Type: article